Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
https://www.zacks.com/stock/news/2252898/bristol-myers-bmy-reports-positive-colorectal-cancer-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252898
Apr 09, 2024 - Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
0
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
https://www.zacks.com/stock/news/2253877/alx-oncology-alxo-posts-upbeat-results-from-lymphoma-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253877
Apr 11, 2024 - ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
0
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
https://www.zacks.com/stock/news/2262685/biotech-stock-roundup-biib-bmy-s-q1-earnings-incy-s-acquisition-updates-from-vrtx?cid=CS-ZC-FT-analyst_blog|earnings_article-2262685
Apr 25, 2024 - Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
0
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
https://www.zacks.com/stock/news/2262623/bristol-myers-bmy-q1-loss-narrower-than-expected-sales-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2262623
Apr 25, 2024 - Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
0
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
https://www.zacks.com/stock/news/2262549/bristol-myers-bmy-q1-earnings-taking-a-look-at-key-metrics-versus-estimates-revised?cid=CS-ZC-FT-fundamental_analysis|nfm-2262549
Apr 25, 2024 - While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0